MDGL
Income statement / Annual
Last year (2023), Madrigal Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Madrigal Pharmaceuticals, Inc.'s net income was -$373.63 M.
See Madrigal Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$527,000.00 |
$467,000.00 |
$405,000.00 |
$471,000.00 |
$112,000.00 |
$96,000.00 |
$77,000.00 |
$156.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$527,000.00 |
-$467,000.00 |
-$405,000.00 |
-$471,000.00 |
-$112,000.00 |
-$96,000.00 |
-$77,000.00 |
-$156.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$272.35 M
|
$245.44 M
|
$205.16 M
|
$184.81 M
|
$72.32 M
|
$25.39 M
|
$24.39 M
|
$15.93 M
|
$54.22 M
|
$68.21 M
|
| General & Administrative
Expenses |
$108.15 M
|
$48.13 M
|
$37.32 M
|
$21.86 M
|
$22.65 M
|
$15.29 M
|
$7.67 M
|
$9.29 M
|
$13.39 M
|
$15.75 M
|
| Selling & Marketing
Expenses |
$108.04 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$108.15 M
|
$48.13 M
|
$37.32 M
|
$21.86 M
|
$22.65 M
|
$15.29 M
|
$7.67 M
|
$9.29 M
|
$13.39 M
|
$15.75 M
|
| Other Expenses |
$0.00 |
$0.00 |
$273,000.00 |
$100,000.00 |
$0.00 |
$200,000.00 |
$350,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$380.50 M |
$293.57 M |
$242.48 M |
$206.67 M |
$94.97 M |
$40.68 M |
$32.06 M |
$25.22 M |
$67.61 M |
$83.95 M |
| Cost And Expenses |
$380.50 M |
$293.57 M |
$242.48 M |
$206.67 M |
$94.97 M |
$40.68 M |
$32.06 M |
$25.22 M |
$67.61 M |
$83.95 M |
| Interest Income |
$19.58 M |
$2.19 M |
$363,000.00 |
$4.33 M |
$11.02 M |
$7.67 M |
$558,000.00 |
$48,303.00 |
$0.00 |
$0.00 |
| Interest Expense |
$12.71 M |
$3.96 M |
$0.00 |
$0.00 |
$11.02 M |
$7.67 M |
$558,000.00 |
$1.16 M |
$1.06 M |
$2.21 M |
| Depreciation &
Amortization |
$527,000.00
|
$467,000.00
|
$405,000.00
|
$471,000.00
|
$112,000.00
|
$96,000.00
|
$77,000.00
|
$156.00
|
$662,000.00
|
$673,000.00
|
| EBITDA |
-$379.97 M
|
-$291.39 M
|
-$242.48 M
|
-$206.67 M
|
-$94.97 M
|
-$40.68 M
|
-$32.06 M
|
-$25.22 M
|
-$66.95 M
|
-$83.28 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$6.87 M
|
-$1.78 M
|
$636,000.00
|
$4.43 M
|
$11.02 M
|
$200,000.00
|
$350,000.00
|
-$1.16 M
|
-$1.06 M
|
-$2.21 M
|
| Income Before Tax |
-$373.63 M |
-$295.35 M |
-$241.85 M |
-$202.24 M |
-$83.95 M |
-$32.81 M |
-$31.15 M |
-$26.39 M |
-$68.67 M |
-$86.16 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$3.96 M |
-$768,000.00 |
-$4.80 M |
-$11.14 M |
$7.87 M |
-$635,000.00 |
-$373.00 |
$0.00 |
$0.00 |
| Net Income |
-$373.63 M |
-$299.31 M |
-$241.08 M |
-$197.44 M |
-$72.81 M |
-$32.81 M |
-$31.15 M |
-$26.39 M |
-$68.67 M |
-$86.16 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-19.99 |
-17.47 |
-14.58 |
-12.78 |
-4.73 |
-2.22 |
-2.54 |
-5.07 |
-401.56 |
-30.62 |
| EPS Diluted |
-19.99 |
-17.47 |
-14.58 |
-12.78 |
-4.73 |
-2.22 |
-2.54 |
-5.07 |
-401.56 |
-30.62 |
| Weighted Average Shares
Out |
$18.69 M
|
$17.14 M
|
$16.54 M
|
$15.45 M
|
$15.39 M
|
$14.80 M
|
$12.24 M
|
$5.20 M
|
$171,012.00
|
$2.81 M
|
| Weighted Average Shares
Out Diluted |
$18.69 M
|
$17.14 M
|
$16.54 M
|
$15.45 M
|
$15.39 M
|
$14.80 M
|
$12.24 M
|
$5.20 M
|
$171,012.00
|
$2.81 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
